

# Efficacy of B<sub>12</sub> Fortified Nutrient Bar and Yogurt in Improving Plasma B<sub>12</sub> Concentrations—Results From 2 Double-Blind Randomized Placebo Controlled Trials

Chittaranjan Yajnik, MD, FRCP<sup>1</sup> ,  
Sonal Kasture, MSc<sup>1</sup>, Vaishali Kantikar, MSc<sup>1</sup>,  
Himangi Lubree, MSc<sup>1</sup>, Dattatray Bhat, MSc<sup>1</sup>,  
Deepa Raut, MSc<sup>1</sup>, Nilam Memane, MSc<sup>1</sup>,  
Aboli Bhalerao, MSc<sup>1</sup>, Rasika Ladkat, MA<sup>1</sup>,  
Pallavi Yajnik, MCom<sup>1</sup>, Sudhir Tomar, PhD<sup>2</sup>,  
Tejas Limaye, PhD<sup>1</sup>, and Sanat Phatak, DM<sup>1</sup>

## Abstract

**Background:** Dietary vitamin B<sub>12</sub> (B<sub>12</sub>) deficiency is common in Indians. Long-term compliance to tablet supplementation is poor in asymptomatic individuals.

**Objective:** To study efficacy of B<sub>12</sub> fortified nutrient bar and yogurt in improving plasma B<sub>12</sub> concentrations in children and adults.

**Methods:** Two double-blind, placebo-controlled directly observed therapy randomized controlled trials were conducted for 120 days: (1) Healthy children (10-13 years) were fed nutrient bar fortified with B<sub>12</sub> (2 µg), multiple micronutrients B<sub>12</sub> (1.8 µg) or placebo. (2) Healthy adults (18-50 years) were fed yogurt fortified with B<sub>12</sub> (2 µg) or *Propionibacterium* (1 × 10<sup>8</sup> cfu/g) or placebo. B<sub>12</sub>, folate, homocysteine, and hemoglobin concentrations were measured before and post intervention.

**Results:** We randomized 164 children and 118 adults; adherence was 96% and 82%, respectively. In children, B<sub>12</sub> fortified bars increased B<sub>12</sub> concentrations significantly above baseline (B<sub>12</sub> alone +91 pmol/L, B<sub>12</sub>+ multiple micronutrients +82 pmol/L) compared to placebo. In adults, B<sub>12</sub> fortified yogurt increased B<sub>12</sub> significantly (+38 pmol/L) but *Propionibacterium* and placebo did not. In both trials, homocysteine fell significantly with B<sub>12</sub> supplementation. Rise of B<sub>12</sub> and fall of homocysteine were

<sup>1</sup> King Edward Memorial Hospital Research Center, Pune, Maharashtra, India

<sup>2</sup> ICAR-National Dairy Research Institute, Karnal, Haryana, India

## Corresponding Author:

Chittaranjan Yajnik, Diabetes Unit, King Edward Memorial Hospital Research Center, Rasta Peth, Pune 411011, Maharashtra, India.

Email: csyajnik@gmail.com

influenced by dose of B<sub>12</sub> and folic acid. There was no significant difference in change of anthropometry and hemoglobin between groups.

**Conclusions:** B<sub>12</sub> fortified foods are effective in improving B<sub>12</sub> status in Indian children and adults. They could be used to improve B<sub>12</sub> status in the national programs for children, adolescents, and women of reproductive age. They could also be used as over-the-counter products.

### Keywords

vitamin B<sub>12</sub> deficiency, B<sub>12</sub> fortified foods, nutrient bar and yogurt, randomized controlled trial, India

## Introduction

Low vitamin B<sub>12</sub> (B<sub>12</sub>) status is widely prevalent in vegetarian populations.<sup>1</sup> Although asymptomatic in many individuals, deficiency may be associated with hematologic, neurocognitive, and cardiovascular manifestations in some.<sup>2</sup> Low maternal B<sub>12</sub> status during pregnancy is linked to increased risk of neural tube defects, preeclampsia, gestational diabetes, preterm delivery, fetal growth restriction, as well as to increased risk of future adiposity and insulin insensitivity in the child.<sup>3,4</sup>

Only bacteria synthesize B<sub>12</sub> naturally, which is incorporated by animals into their tissues.<sup>5</sup> Humans obtain B<sub>12</sub> from consumption of such animal derived foods (meat, liver, fish, eggs, and milk). Plant foods do not contain B<sub>12</sub>. Low B<sub>12</sub> status in developing countries is largely attributed to low intake of animal-origin foods, either because of cultural and religious practices (Hindu, Jain, and Buddhist) or due to poverty, which precludes expensive nonvegetarian foods from diet.<sup>6</sup> Low B<sub>12</sub> status is common in Indians, both in those living in India as well as those migrated abroad.<sup>7</sup> This is largely attributable to vegetarianism but not to pernicious anemia (malabsorption due to lack of intrinsic factor). Our research showed that B<sub>12</sub> deficiency is common in and around Pune, India,<sup>7</sup> despite normal B<sub>12</sub> absorption in >85% of the population.<sup>8</sup> Increasing intake of animal origin foods to improve vitamin B<sub>12</sub> status has obvious practical limitations in Indians. In our community-based trials, B<sub>12</sub> status improved by supplementation with capsules containing 2 µg B<sub>12</sub> per day<sup>9</sup> or drinking 400 mL of milk daily.<sup>10</sup>

Although low-dose supplements are successful in improving B<sub>12</sub> status in a trial setting, they

are unlikely to have a big impact in public health owing to poor long-term adherence in asymptomatic individuals. Food fortification may be an effective way to improve B<sub>12</sub> status in Indians and other vegetarian populations. Fortification of breakfast cereals and milk with B<sub>12</sub> is common in many countries but not in India. In recent years, probiotics including *Propionibacterium* have been claimed to improve B<sub>12</sub> status.<sup>11</sup> This could also be of help in Indians and warrants further research.

As part of our research to improve B<sub>12</sub> status of the population, we tested 2 B<sub>12</sub> fortified food items: (1) A nutrient bar in school children, and (2) Yogurt in adults, for their efficacy to improve B<sub>12</sub> status. We also tested a *Propionibacterium* species probiotic, claimed to produce substantial quantities of B<sub>12</sub>, as a separate fortificant for yogurt.

## Methods

### Study Design and Intervention

We conducted 2 double-blind, placebo-controlled, randomized, directly observed therapy (DOT) trials. We excluded those with chronic medical illness and those with very low B<sub>12</sub> concentration (<100 pmol/L) or anemia (hemoglobin <10 g/dL) for ethical reasons and advised them appropriate treatment. We also excluded those on regular vitamin supplementation (>10 days). Randomization was computer generated, and stratification was based on baseline B<sub>12</sub> and hemoglobin concentrations (below and above median) to ensure comparable distribution. All participants were instructed not to take any vitamin supplements during the trial. Intervention

products were consumed under observation (DOT). Adherence was calculated for each participant by calculating the number of days of attendance during the trial. Adverse events were recorded.

### Nutrient Bar Trial

This was conducted in a village school (Pabal, Pune District, ~70 km from Pune) in children aged 10 to 13 years. School authorities approved participation in the trial. We arranged a meeting with the school children and their parents to explain the trial and invited them to sign an assent and consent. Included children were randomized to 3 groups to receive one bar per day, fortified with (a) 2 µg B<sub>12</sub> or (b) multiple micronutrients (MMN), including 1.82 µg B<sub>12</sub> (United Nations Children's Emergency Fund guidelines)<sup>12</sup> (Supplementary Table 1), or (c) no added micronutrients (placebo). All bars were similar in appearance and taste. The children ate the bars in the school in the morning recess, directly observed by research staff. The duration of supplementation was 120 consecutive school days, from September 2011 to March 2012.

### Yogurt Trial

The yogurt study was conducted in volunteers aged 18 to 50 years at the KEM Hospital, Pune. Hospital staff members and their friends were invited to enroll through notice board advertisement. Eligible participants were randomized into 3 groups to receive 100 gm yogurt fortified with (a) 2 µg B<sub>12</sub>, (b) 1 × 10<sup>8</sup> cfu/g *Propionibacterium*, and (c) without any additions (placebo). The strain used for fortification (*Propionibacterium freudenreichii* subsp. *freudenreichii* ATCC 6207, GRAS certified) was provided by the National Dairy Research Institute and was recommended because it was known to produce B<sub>12</sub> in vitro.<sup>13</sup> The 3 yogurt preparations were similar in appearance, taste, flavor, and smell. The yogurt was eaten under supervision for 120 consecutive working days between December 2013 and May 2014.

### Ethics


In nutrient bar trial, informed written assent was obtained from the children, and consent was signed by the parents. In yogurt trial, participants provided written consent. Both trials were approved by KEM Hospital Research Centre Ethics Committee. For the nutrient bar trial, permissions were obtained from the school authorities and the District Health Officer. The trials were registered with the Clinical Trials Registry of India (CTRI/2012/07/002799 -nutrient bar, CTRI/2015/04/005703 -yogurt).

### Measurements

Height was measured to the nearest 0.1 cm using a stadiometer (CMS Instruments) and body weight to the nearest 0.01 kg using an electronic weighing scale (Model no. HD-358, Tanita Corporation). At baseline, nonfasting venous blood sample was collected in ethylenediaminetetraacetic acid vacutainers for measurements of hemogram, B<sub>12</sub>, folate, and homocysteine. Hemogram was measured on a Beckman Coulter Analyzer (AC.T diff) on the same day. Plasma aliquots were stored (−70 °C) until further analysis. B<sub>12</sub> was measured by a microbiological assay using a colistin sulfate-resistant strain of *Lactobacillus leichmannii* (Coefficient of variation (CV) <8%).<sup>14,15</sup> Plasma total homocysteine (homocysteine) was measured by fluorescence derivative of monobromobimane using HPLC (inter and intra batch CV <4%). Plasma folate was measured by a microbiological assay using a chloramphenicol-resistant strain of *Lactobacillus Casei* (inter and intra CV <8%).<sup>16,17</sup> The blood and clinical measurements were repeated at the end of the trial.

### Statistical Analysis

For children, we calculated sample size required in each group to demonstrate a 50% rise in plasma B<sub>12</sub> concentrations at 5% significance level and found that 55 individuals allowing a dropout rate of 10% will provide a power of more than 90%. For adults, we calculated sample size required in each group to demonstrate a



**Figure 1.** Flow of participants in 2 trials. (A) Nutrient bar trial was conducted in village school children. (B) Yogurt trial was conducted in healthy adult volunteers in an urban setup.

30% rise in plasma B<sub>12</sub> concentrations at 5% significance level and found that 45 individuals allowing a dropout rate of 10% will provide a power of more than 80%.

Data are presented as median (25th-75th percentile) for continuous variables and as percentages for categorical variables. Skewed variables were log normalized before analysis. Significance of the differences between baseline and end of trial levels of clinical and biochemical measurements were tested by paired *t* test for continuous variables and by  $\chi^2$  test for categorical variables. Significance of difference from placebo group was tested by *t* test. Analysis was by intention-to-treat method. The participants who were lost to follow-up were analyzed by “last observation carried forward” method.

We used multivariate regression analysis to calculate predictors of change in B<sub>12</sub> and homocysteine concentrations after intervention. We normalized the variables by converting them to standard deviation scores. We used age, sex, BMI, baseline concentrations of B<sub>12</sub> or homocysteine,

and dose of B<sub>12</sub> and folic acid in intervention group as determinants of change. In the yoghurt trial, there were no folic acid supplements; therefore, we used change in folate concentrations.


## Results

### Nutrient Bar Trial

We approached 180 school children and their parents to participate in the trial, of whom 178 (99%) agreed. Fourteen children were excluded: 13 with B<sub>12</sub> < 100 pmol/L and 1 with anemia; they were prescribed appropriate treatment (Figure 1A). The 164 randomized children (57% girls) were 11.3 (10.9-12.0) years old, 139.4 (134.5-144.5) cm tall and with a weight of 28.8 (25.2-33.4) kg; there was no significant difference between groups. Plasma B<sub>12</sub>, folate, and homocysteine concentrations were comparable (Table 1).

After intervention, B<sub>12</sub> rose significantly by median 91 pmol/L in B<sub>12</sub> alone group and by 82 pmol/L above the baseline in B<sub>12</sub> + MMN group





**Figure 2.** (Box plot) Change in plasma vitamin B<sub>12</sub> and homocysteine concentrations after supplementation with fortified food products for 120 days. Differences between the groups are tested by Mann-Whitney *U* test. *P* values are given as \**P* < .05, \*\**P* < .01, \*\*\**P* < .001. B-12, vitamin B<sub>12</sub> (2.0 µg); MMN, multi micronutrient (1.8 µg vitamin B<sub>12</sub>); NS, nonsignificant; *Propionibacterium*: *Propionibacterium freudenreichi* ( $1 \times 10^8$  cfu/g).

homocysteine concentrations were comparable (Table 3).

After intervention, B<sub>12</sub> rose significantly by median 38 pmol/L above the baseline in the B<sub>12</sub> group (*P* < .001) and homocysteine decreased by median 2.7 µmol/L (*P* < .001; Figure 2). There were no significant changes in B<sub>12</sub> or homocysteine in the *Propionibacterium* and the placebo groups. There was a small rise in folate concentrations in all groups, but no significant changes in hemoglobin concentrations and weight in any group.

**Comparison with placebo.** The rise in B<sub>12</sub> concentration and fall in homocysteine concentration from baseline was higher in B<sub>12</sub> fortified yogurt group compared to the placebo and *Propionibacterium* fortified groups (Figure 2).

During the intervention 6 participants discontinued from the B<sub>12</sub>, 9 from *Propionibacterium*

and 9 from plain yogurt group; all for reasons not related to intervention. Ninety-four (82%) participants completed the trial (Figure 1B). Mean adherence for daily yogurt consumption was similar in 3 groups (≥82%). There was one serious adverse event (hospital admission for incidental illness) not related to the intervention product.

**Predictors of B<sub>12</sub> and homocysteine change.** Dose of B<sub>12</sub> in the intervention groups predicted larger rise in B<sub>12</sub> concentrations. Similarly, fall in homocysteine concentration was predicted by the B<sub>12</sub> dose, and higher baseline homocysteine concentration, but not by change in folate levels (Table 2).

## Discussion

Our results show that regular consumption of B<sub>12</sub> fortified nutrient bar or yogurt for 4 months

**Table 2.** Multivariate Regression for Change in B<sub>12</sub> and Homocysteine.

Outcome and Exposures	Nutrient bar		Yoghurt	
	Beta	P value	Beta	P value
Rise in B <sub>12</sub> (post intervention – baseline)				
Age at screening (years)	-0.030	.676	0.019	.845
Sex (1: Male, 2: Female)	-0.070	.328	0.010	.919
BMI at screening (kg/m <sup>2</sup> )	-0.118	.102	-0.091	.350
B <sub>12</sub> at baseline (pmol/L)	0.234	.001	0.122	.214
Dose of B <sub>12</sub> <sup>a</sup>	0.408	.0001	0.206	.033
Fall in homocysteine (baseline – post intervention)				
Age at screening	-0.018	.732	0.016	.856
Sex (1: Male, 2: Female)	-0.118	.031	0.021	.812
BMI at screening	-0.049	.361	-0.114	.203
Homocysteine at baseline (pmol/L)	0.474	.0001	0.307	.001
Rise in folate (pmol/L)	NA	NA	0.133	.138
Dose of B <sub>12</sub> <sup>a</sup>	0.440	.0001	0.257	.004
Dose of folic acid <sup>b</sup>	0.276	.0001	NA	NA

Abbreviation: MMN, multiple micronutrient.

<sup>a</sup>Dose of B<sub>12</sub>: (For nutrient bar: B<sub>12</sub>: 2 µg, MMN: 1.8 µg, placebo: 0 µg), (For Yoghurt: B<sub>12</sub>: 2 µg, *Propionibacterium*: 0 µg, placebo: 0 µg).

<sup>b</sup>Dose of folic acid: (For nutrient bar: B<sub>12</sub>: 0 µg, MMN: 180 µg, placebo: 0 µg).

Yogurt Trial

significantly improved B<sub>12</sub> status. Our population has high prevalence of B<sub>12</sub> deficiency, and we used near Recommended Dietary Allowance doses in our trials to make it public health relevant. Directly observed therapy design ensured high adherence and allowed us to explore the full potential of fortification with these doses. Placebo comparison helped investigate the specific effects of vitamin B<sub>12</sub> interventions. Nutrient bar and yogurt are 2 commonly eaten food items in India and were well accepted by the participants. Our results make it an attractive public health proposition. Rather disappointingly, the *Propionibacterium* probiotic at the recommended dose did not influence B<sub>12</sub> status.

The response of circulating B<sub>12</sub> concentrations was proportional to the dose of B<sub>12</sub>, and in turn reflected in reduction of circulating homocysteine concentrations. This indicates an improved methylation status of the body in both the children and the adults. Addition of other micronutrients (folic acid, B6, and B2) to B<sub>12</sub> had an additional effect on lowering of homocysteine in children. In addition to the expected effect of the dose of B<sub>12</sub>, higher baseline concentration of

B<sub>12</sub> predicted a higher rise in B<sub>12</sub> concentration. The latter finding was also seen in our previous study which showed that higher baseline B<sub>12</sub> concentration predicted higher absorption of the supplemented vitamin.<sup>8</sup> Higher fall in homocysteine concentration was predicted by its higher baseline concentration and by dose of B<sub>12</sub> and folic acid. In our trials, B<sub>12</sub> supplementation had no effect on hemoglobin concentration which might be because of its satisfactory levels at baseline or a requirement for relatively higher doses of B<sub>12</sub> for hematological effects. In another study of more severely B<sub>12</sub> deficient adolescent girls, we were able to show improvement in hemoglobin concentration (and peripheral nerve function) with similar daily dose of vitamin B<sub>12</sub> but continued over a longer period of 11 months.<sup>18</sup> Our results support fortification of commonly eaten food items as vehicles for improving B<sub>12</sub> status in populations with low B<sub>12</sub> status who do not have the problem of defective absorption.

There are only a few studies of B<sub>12</sub> fortification to improve the vitamin status. They have been done in preschool children (MMN)<sup>19,20</sup> and in elderly population (B<sub>12</sub>),<sup>21</sup> the 2 groups

**Table 3.** Yoghurt Trial: Comparison Within and Between Groups.<sup>a</sup>

Outcome	Placebo (n = 40)			Propionibacterium (n = 39)			B <sub>12</sub> (n = 39)			Significance of difference between post-intervention concentrations <sup>b</sup>
	Baseline	120 days	P <sup>c</sup>	Baseline	120 days	P <sup>c</sup>	Baseline	120 days	P <sup>c</sup>	
Biochemistry										
B <sub>12</sub> (pM)	151 (123, 239)	167 (120, 234)	.670	167 (125, 214)	168 (142, 216)	.460	142 (118, 185)	207 (154, 278)	<.001	0.212
Folate (nmol/L)	14 (11.0, 22.3)	18.8 (14.5, 24.4)	.062	18.1 (13.7, 23.6)	20.5 (17.3, 28.4)	.009	16 (12.1, 22.6)	19 (17.2, 27.8)	.001	0.104
tHcy (µmol/L)	19.0 (11.9, 34.9)	9.3 (2.0, 32.6)	.675	16.9 (12.0, 25.0)	17.3 (12.1, 23.4)	.815	22.7 (14.3, 43.5)	17.3 (12.9, 29.8)	.001	0.426
Hemoglobin (g/dl)	11.5 (10.0, 12.4)	11.9 (10.5, 13.0)	.015	11.2 (9.5, 12.0)	11.3 (10.1, 12.3)	.018	11.4 (10.4, 13.4)	11.6 (10.2, 14.0)	.539	0.511
Compliance										
			77%							84%
										85%

Abbreviation: tHcy, total homocysteine.

<sup>a</sup>Numbers are median (25th-75th percentile). (The analysis was by intention-to-treat and those lost to follow-up were ascribed final value by last observation carried forward method).

<sup>b</sup>Difference between the groups by Mann-Whitney U test (nonparametric).

<sup>c</sup>Difference within the groups are tested by paired t test (parametric).

commonly thought to be at risk of low B<sub>12</sub> status. The vehicles for B<sub>12</sub> were rice, milk, wheat flour (consumed as bread), common salt, and breakfast cereals.<sup>19,20,22-24</sup> In a population with high burden of low B<sub>12</sub> status, a multipronged food fortification program may be more successful than isolated food product fortification to improve the B<sub>12</sub> status. In our own and others' experience, supplementation with tablets in asymptomatic individuals suffers rapid reduction in adherence. Such supplementation also has complex logistic requirements in field operations in large populations.

We conducted our trials in a population with high prevalence of low B<sub>12</sub> status, making it relevant to many such populations in India and other developing countries.<sup>25</sup> Participation rates were high. The placebo-controlled, randomized design ensured an unequivocal result and high-quality evidence for both trials. The use of DOT approach ensured near complete compliance (≥95%) in children, thus allowing full potential of the intervention to be exploited. Our findings will be directly applicable to vulnerable populations (children, adolescents, young adults, and pregnant women), where low B<sub>12</sub> status may have major implications for growth, development, and reproductive health. Possible weaknesses include small sample size and a relatively short period of intervention. Relatively lower adherence in a DOT trial in the adults (average 82%) is a reflection of multiple demands on time in working middle class and not a reflection of the investigational product. Even at this attendance, there was a rewarding improvement in B<sub>12</sub> status.

In summary, we used fortified versions of 2 commonly consumed food items to improve B<sub>12</sub> status in deficient populations. This approach appears superior to use of vitamin tablets, which has proved difficult to sustain over longer periods of time in asymptomatic population. Both food items additionally provide calories, proteins, and other nutrients, and therefore could be easily adopted in national programs of feeding malnourished children and adults, as well as in the Mid-day Meal programs in schools. Both food items could be made at low cost by small-scale home industry promoting local economy. These factors will help the

policy-makers to make appropriate decisions in deserving populations. Further research should investigate benefits of B<sub>12</sub> supplementation to physical, cognitive, and reproductive outcomes in deficient populations.

### Authors' Note

C.Y., S.T., and P.Y. conceptualized and planned the study. S.K., V.K., H.L., R.L., P.Y., and C.Y. were involved in the trial conduct. D.B., D.R., and N.M. performed all the laboratory measurements. Statistical analysis was done by T.L. and A.B. C.Y., T.L., S.P., and D.B. wrote the manuscript.

### Acknowledgments

The authors thank the team at Diabetes Unit, KEM Hospital Research Centre, Pune, for practical assistance during the trial (Charudatta Joglekar, Sonali Wagle, Vidya Mudliar, Komal Adawani, Rucha Wagh). The authors thank Dr Arun Nanivadekar and Dr Mohan Gupte for their guidance. The authors are grateful to the participants of both the trials.

### Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by Department of Bioethnology (DBT), New Delhi, India. DSM India kindly provided nutrient bars for the study. Hi Tech Biosciences India Limited, Pune, produced yogurt for the trial.

### ORCID iD

Chittaranjan Yajnik  <https://orcid.org/0000-0002-8482-6349>

### Supplemental Material

Supplemental material for this article is available online.

### References

1. Green R, Allen LH, Bjørke-Monsen AL, et al. Vitamin B<sub>12</sub> deficiency. *Nat Rev Dis Primers*. 2017;3:17040.
2. Stabler SP. Clinical practice. Vitamin B<sub>12</sub> deficiency. *N Engl J Med*. 2013;368(2):149-160.
3. Yajnik C. Vitamin B<sub>12</sub>: an intergenerational story. *Nestle Nutr Inst Workshop Ser*. 2020;93:91-102.
4. Behere RV, Deshmukh AS, Otiv S, Gupte MD, Yajnik CS. Maternal Vitamin B<sub>12</sub> Status during pregnancy and its association with outcomes of pregnancy and health of the offspring: a systematic review and implications for policy in India. *Front Endocrinol*. 2021;12:619176.
5. Smith AD, Warren MJ, Refsum H. Vitamin B<sub>12</sub>. *Adv Food Nutr Res*. 2018;83:215-279.
6. Allen LH. Causes of vitamin B<sub>12</sub> and folate deficiency. *Food Nutr Bull*. 2008;29(2 suppl): S20-S37.
7. Yajnik CS, Deshpande SS, Lubree HG, et al. Vitamin B<sub>12</sub> deficiency and hyperhomocysteinemia in rural and urban Indians. *J Assoc Physicians India*. 2006;54:775-782.
8. Bhat DS, Thuse N, Joglekar C, et al. 6E-3 Absorption of oral vitamin B<sub>12</sub> in Indians; the Pune maternal nutrition study. *Early Hum Dev*. 2007;83.10. 1016/S0378-3782(07)70167-6
9. Deshmukh US, Joglekar CV, Lubree HG, et al. Effect of physiological doses of oral vitamin B<sub>12</sub> on plasma homocysteine: a randomized, placebo-controlled, double-blind trial in India. *Eur J Clin Nutr*. 2010;64(5):495-502.
10. Naik S, Bhide V, Babhulkar A, et al. Daily milk intake improves vitamin B-12 status in young vegetarian Indians: an intervention trial. *Nutr J*. 2013;12:136.
11. Poonam Pophaly SD, Tomar SK, De S, Singh R. Multifaceted attributes of dairy propionibacteria: a review. *World J Microbiol Biotechnol*. 2012; 28(11):3081-3095.
12. World Health Organization. Preventing and controlling micronutrient deficiencies in populations affected by an emergency. Joint statement by the World Health Organization, the World Food Programme and the United Nations Children's Fund. 2007. Accessed May, 2021. <https://tinyurl.com/y9xfhgpp>

13. Fang H, Kang J, Zhang D. Microbial production of vitamin B<sub>12</sub>: a review and future perspectives. *Microb Cell Fact*. 2017;16(1):15.
14. Kelleher BP, Walshe KG, Scott JM, O'Broin SD. Microbiological assay for vitamin B<sub>12</sub> with use of a colistin-sulfate-resistant organism. *Clin Chem*. 1987;33(1):52-54.
15. Kelleher BP, Broin SD. Microbiological assay for vitamin B<sub>12</sub> performed in 96-well microtitre plates. *J Clin Pathol*. 1991;44(7):592-595.
16. Horne DW, Patterson D. Lactobacillus casei microbiological assay of folic acid derivatives in 96-well microtiter plates. *Clin Chem*. 1988; 34(11):2357-2359.
17. Tamura T, Freeberg LE, Cornwell PE. Inhibition of EDTA of growth of Lactobacillus casei in the folate microbiological assay and its reversal by added manganese or iron. *Clin Chem*. 1990; 36(11):1993.
18. Yajnik CS, Behere RV, Bhat DS, et al. A physiological dose of oral vitamin B-12 improves hematological, biochemical-metabolic indices and peripheral nerve function in B-12 deficient Indian adolescent women. *PLoS One*. 2019;14(10): 0223000.
19. Thankachan P, Rah JH, Thomas T, et al. Multiple micronutrient-fortified rice affects physical performance and plasma vitamin B-12 and homocysteine concentrations of Indian school children. *J Nutr*. 2012;142(5):846-852.
20. Kuriyan R, Thankachan P, Selvam S, et al. The effects of regular consumption of a multiple micronutrient fortified milk beverage on the micronutrient status of school children and on their mental and physical performance. *Clin Nutr*. 2016; 35(1):190-198.
21. Brito A, Verdugo R, Hertrampf E, et al. Vitamin B-12 treatment of asymptomatic, deficient, elderly Chileans improves conductivity in myelinated peripheral nerves, but high serum folate impairs vitamin B-12 status response assessed by the combined indicator of vitamin B-12 status. *Am J Clin Nutr*. 2016;103(1):250-257.
22. Garrod MG, Buchholz BA, Miller JW, Haack KW, Green R, Allen LH. Vitamin B<sub>12</sub> Added as a fortificant to flour retains high bioavailability when baked in bread. *Nucl Instrum Methods Phys Res B*. 2019;438:136-140.
23. Vinodkumar M, Rajagopalan S. Multiple micronutrient fortification of salt. *Eur J Clin Nutr*. 2009; 63(3):437-445.
24. Powers HJ, Stephens M, Russell J, Hill MH. Fortified breakfast cereal consumed daily for 12 wk leads to a significant improvement in micronutrient intake and micronutrient status in adolescent girls: a randomised controlled trial. *Nutr J*. 2016;15(1):69.
25. McLean E, de Benoist B, Allen LH. Review of the magnitude of folate and vitamin B<sub>12</sub> deficiencies worldwide. *Food Nutr Bull*. 2008;29(2 suppl): S38-S51.